Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - Circulation, 2021 - Am Heart Assoc
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease
JJV McMurray, DC Wheeler, BV Stefánsson… - Circulation, 2021 - discovery.ucl.ac.uk
BACKGROUND: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and kidney events …
chronic kidney disease. We examined the relative risk of cardiovascular and kidney events …
[PDF][PDF] Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease
JJV McMurray - academia.edu
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and kidney events …
chronic kidney disease. We examined the relative risk of cardiovascular and kidney events …
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - 2021 - pubmed.ncbi.nlm.nih.gov
Background Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - Circulation, 2021 - diva-portal.org
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - Circulation, 2021 - research.rug.nl
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and kidney events …
chronic kidney disease. We examined the relative risk of cardiovascular and kidney events …
[PDF][PDF] Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - Circulation, 2021 - gov.br
BACKGROUND: Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - Circulation, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Dapagliflozin reduces the risk
of end-stage renal disease in patients with chronic kidney disease. We examined the …
of end-stage renal disease in patients with chronic kidney disease. We examined the …
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - Circulation, 2020 - europepmc.org
Background Dapagliflozin reduces the risk of end-stage renal disease in patients with
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
[引用][C] Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
Circulation, 2021 - core.ku.dk
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and
Without Cardiovascular Disease - Fitmum: Fitness for good health of mother and child Topic …
Without Cardiovascular Disease - Fitmum: Fitness for good health of mother and child Topic …